Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Tina VilsbøllElla EkholmEva JohnssonRicardo Garcia-SanchezNalina DronamrajuSerge A JabbourMarcus LindPublished in: Diabetes, obesity & metabolism (2020)
DAPA + SAXA treatment was non-inferior to INS in reducing HbA1c and body weight, and in achieving optimal glycaemic control without hypoglycaemia in patients with T2D 52 weeks after initiation.